Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
AUROBINDO May 31,2021 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI -400 051 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA C
Slide 2: Aurobindo Pharma Ltd Earnings Presentation May 2021
AUROBINDO PHARMA LTD Earnings Presentation May 2021
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any part hereof
Slide 4: Index
Index Q4FY21 & FY21 Business & Financial Highlights 04 Financial Performance 13 Filing Snapshot 16
Slide 5: Q4FY21 & FY21 Business & Financial Highlights
1 Q4FY21 & FY21 Business & Financial Highlights
Slide 6: Consolidated Financial Performance – FY21
Consolidated Financial Performance – FY21 In Rs Cr Revenue EBITDA Reported Profit After Tax 7% YoY 10% YoY 88% YoY 21.1% 21.5% EBITDA Margin
Slide 7: Consolidated Financial Performance (Ex-Natrol) – FY21
Consolidated Financial Performance (Ex-Natrol) – FY21 In Rs Cr Revenue EBITDA Adjusted Profit After Tax* 8% YoY 9% YoY 10% YoY 20.9% 21.1% EBITDA Margin *Net profit after JV share, minority interest excluding exceptional items (net of tax)
Slide 8: Consolidated Financial & Business Highlights – FY21
Consolidated Financial & Business Highlights – FY21 Revenue from operations at Rs. 24,774.6 Cr, witnessed a growth of 7.3% YoY Research & Development spend at Rs. 1,510 Cr in FY21, 6.1% of revenue Vs. Rs. 958 Cr in FY20, 4.1% of revenue EBIDTA before Forex and Other income at Rs. 5,333.4 Cr, an incr
Slide 9: Consolidated Financial Performance (Ex-Natrol) – Q4 FY21
Consolidated Financial Performance (Ex-Natrol) – Q4 FY21 In Rs Cr Revenue EBITDA Adjusted Profit After Tax* 2% YoY 2% YoY 5% YoY 22.2% 21.2% EBITDA Margin *Net profit after JV share, minority interest excluding exceptional items (net of tax) Q4FY20 EBITDA includes MEIS benefits and net profit includ
Slide 10: Consolidated Financial & Business Highlights – Q4 FY21
Consolidated Financial & Business Highlights – Q4 FY21 Revenue from operations at Rs. 6,001.5 Cr, declined by 2.5% YoY Research & Development (R&D) spend at Rs. 457 Cr, 7.6% of revenue vs. Rs. 390 Cr, 6.1% of revenue in Q3FY21 EBIDTA before Forex and Other income at Rs. 1,274.7 Cr, down by 5.0% YoY;
Slide 11: Consistent Quarterly Performance
Consistent Quarterly Performance Revenue Ex Natrol (Rs Cr) US Revenue Ex Natrol ($ Mn) EBITDA (Rs Cr) Net Debt to Equity* 0.16 0.08 0.08 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 -0.04 -0.04 *At the end of the quarter
Slide 12: US Business Performance Highlights
US Business Performance Highlights Revenue (Rs Cr) Revenue Mix - FY21 Total Injectables 21.2%% US Formulations • US revenue in Q4FY21 declined by 4.5% YoY to Rs. 2,856.0 Cr, accounting 47.6% of consolidated revenue. Excluding Natrol sales, the revenue increased by 5.3% YoY. On constant currency basi
Slide 13: Europe, ARV, Growth Markets, API Business Performance Highlights
Europe, ARV, Growth Markets, API Business Performance Highlights Europe Revenues Growth Markets Revenues* ARV Revenues API Revenues** • Europe revenue in Q4FY21 decreased by • Revenue from Growth Markets • ARV business revenue for • In Q4FY21, API business posted a 6.0% YoY to Rs. 1,552.6 Cr due to
Slide 14: Financial Performance
{ 2] AUROBINDO Financial Performance
Slide 15: Consolidated Financial Performance
Consolidated Financial Performance Rs Cr Q4FY21 Q4FY20 (%) Chg Q3FY21 (%) Chg FY21 FY20 (%) chg Revenue from operations 6,001.5 6,158.4 -2.5 6,364.9 -5.7 24,774.6 23,098.5 7.3 Gross Profit 3,594.4 3,655.1 -1.7 3,792.6 -5.2 14,872.2 13,363.3 11.3 Gross Margin 59.9% 59.4% 59.6% 60.0% 57.9% Overheads 2
Slide 16: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (Rs Cr) Mar-18 Mar-19 Mar-20 Dec-20 Mar-21 Closing Rate1 US$ = INR 65.17 69.155 75.6650 73.07 73.11 731 1,007 732 680 674 Fx Loan restated in INR 4,766.9 6,959.0 5,549.2 4,970.6 4.928.8 Rupee Loan 4.1 8.1 16.9 114.4 43.6 248 Gross Debt 4,771.0 6,967.1 5,566.1 5
Slide 17: Filing Status
r °o AUROBIN DO alihter lif Filing Status
Slide 18: US Filings Snapshot as on 31st Mar 2021
US Filings Snapshot as on 31st Mar 2021 ANDA Filings Addressable Therapy ANDAs Market Size (US$ Bn) Non - Injectables CNS 110 22.9 Injectables CVS 93 31.0 ARV** 39 3.2 Gastroenterological 35 3.3 SSP & Cephs 31 0.5 Oncology & Hormones 42 12.6 Anti Diabetic 21 20.9 Controlled Substances 15 1.1 Unit wi
Slide 19: Filing Snapshot
Filing Snapshot As at As at As at As at As at As at As at Category Approvals Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Formulations US* 376 398 429 478 541 586 639 468 (FA: 439, TA:29) 2,722 Dossiers (316 Europe** 1,756 2,224 2,521 2,848 3,003 3,214 3,374 products) 219 Registrations (108 SA**
Slide 20: Thank You
Thank You Investors Contact Investor Relations team ir@aurobindo.com 040-66725401